Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESIST-PC: 177Lu-PSMA-617 in mCRPC
NCT03042312Phase 2Terminated
- Sponsor
- Endocyte
- Start
- Jul 2017
- Primary completion
- Jan 2020
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium-177 PSMA in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Endocyte. Primary endpoints: Treatment Emergent Adverse Events up to 24 months and Prostate-Specific Antigen Response at Week 12. Started Jul 2017; status: terminated.
02
Drugs
lutetium-177 PSMA
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03042312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042312.